Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.
David brings experience in business development as well as executive managerial experience in public companies, Sanofi and BiolineRx.
Matt’s 20+ years of capital markets, strategic corporate finance and business operations experience spans both industry and Wall Street as an equity research analyst and as CFO and Head of Corporate Affairs, Investor Relations and Communications in biotechnology companies
Hagop is an experienced oncology drug developer with tenures in several pharmaceutical and biotech companies, including as Chief Medical Officer at ImClone-Lilly and as President of R&D at Ziopharm. He was involved in the development and approval of multiple oncology biologics, such as Erbitux®, Cyramza®, and Taxotere®.